慶應義塾大学 · 医学
Kawakubo教授の研究室は、がんの発症・進行機構と治療戦略の解明を柱としており、特に乳腺がんや食道がんにおける腫瘍抑制遺伝子BTG2の機能とその臨床的意義を、分子細胞生物学的・臨床的アプローチを融合して研究しています。また、がん治療における予後予測や治療反応のバイオマーカーの特定、特にニュアドジュバント療法の有効性と最適な治療戦略の確立にも注力しています。
Figures are computed from collected data and may differ slightly.
The B-cell translocation gene-2 (BTG2) is present in the nuclei of epithelial cells in many tissues, including the mammary gland where its expression is regulated during glandular proliferation and differentiation in pregnancy. In immortalized mammary epithelial cells and breast cancer cells, BTG2 protein localized predominantly to the nucleus and cytoplasm, respectively. The highly conserved domains (BTG boxes A, B, and C) were required for regulating localization, suppression of cyclin D1 and
Neoadjuvant DCF therapy showed a remarkable survival advantage in surgically resectable ESCC patients, especially in patients who were 75 years old or younger. The current real-world evidence will encourage recommendations for DCF as a standard regimen in neoadjuvant chemotherapy-based treatment strategy for ESCC.
It was found that postoperative recurrence in responders occurred in the regional field mostly as a solitary lesion without the distant failure, indicating that the residual tumor cells can be eliminated by additional chemoradiotherapy.
The prognostic value of classification using pStage and the pathological response was successfully validated using real-world data in Japan. This result would guide appropriate treatment for patients with esophageal squamous cell carcinoma who received neoadjuvant chemotherapy followed by esophagectomy.
Open papers in the app to read, cite, and organize with AI.
